; will ; project ; potential ; or similar statements are forward-looking statements. PharmAthene disclaims any intent or obligation to update these forward-looking statements other than as required by law. Risks and uncertainties include risk associated with the reliability of the results of the studies relating to human safety and possible adverse effects resulting from the admini

"; "will"; "project"; "potential"; or similar statements are forward-looking statements. PharmAthene disclaims any intent or obligation to update these forward-looking statements other than as required by law. Risks and uncertainties include risk associated with the reliability of the results of the studies relating to human safety and possible adverse effects resulting from the administration of the PharmAthene's product candidates, unexpected funding delays and/or reductions or elimination of U.S. government funding for one or more of the PharmAthene's development programs, the award of government contracts to our competitors, unforeseen safety issues, challenges related to the development, scale-up, technology transfer, and/or process validation of manufacturing processes for our product candidates, unexpected determinations that these product candidates prove not to be effective and/or capable of being marketed as products, as well as risks detailed from time to time in PharmAthene's Forms 10-K and 10-Q under the caption "Risk Factors" and in its other reports filed with the U.S. Securities and Exchange Commission. In particular, there is significant uncertainty regarding the level and timing of sales of ST-246 and when and whether it will be approved by the U.S. FDA and corresponding health agencies around the world. Further, we cannot predict with certainty when SIGA Technologies, Inc. ("SIGA") will commence delivering any product or will begin recognizing profit on the sale of ST-246 and there can be no assurance that any profits received by SIGA and paid to PharmAthene will be significant. We note that SIGA has publicly stated it intends to appeal the Court of Chancery decision, and there can be no assurances that the decision will not be reversed or that the remedy will not otherwise be modified. In addition, to the extent that there is an appeal, we cannot predict how long such appeal will delay the receipt of payments, if any, from'/>"/>

(Date:3/3/2015)... 3, 2015 Synthetic Biologics, Inc. (NYSE MKT: SYN), a ... a focus on protecting the microbiome, announced today that ... at the 27th Annual ROTH Conference being held on March ... in Dana Point, CA. Mr. ... at 1:00 p.m. (Pacific Time). A live webcast ...

(Date:3/3/2015)... , March 2, 2015 Phillip Sharp, Institute Professor at ... of the Department of Biology and the Koch Institute for Integrative ... at Heritage Day , May 14, at the ... the Othmer Gold Medal since it was first awarded ... "In 1977 Phil Sharp gave the scientific world ...

... Bay, Wis. - Whenever the title executive vice president ... an established part of management. So it is with Judy ... National following a career that she thought was winding ... Green Bay-based provider of global transportation, logistics, and intermodal services, ...

... students are no longer interested in technology careers? , ... Area Technical College has won first place in ... beating four teams from Minnesota, and later advanced to ... third place. , ,The competitions were open to students ...

... a series of articles on raising capital from investors. This installment ... the time when raising equity capital, the offering terms are summarized ... When dealing with angel investors , it is typical ... prospective angel investors will want to negotiate the initial term sheet, ...

(Date:2/24/2015)... Research and Markets ( http://www.researchandmarkets.com/research/sxwl43/global_2d_gesture ... "Global 2D Gesture Recognition Market 2015-2019" report ... forecast the Global 2D Gesture Recognition market to ... period 2014-2019 The increased demand for ... of the major trends in the market. The ...

... interested in natural history but it also challenges those people ... life on Earth. Thats the view of Dr Robert Lambert, ... of Nottingham, who has just returned from the Antarctic in ... Antarctica Tour Operators (IAATO). Dr Lambert, who is a ...

... University of Missouri scientist Ray Semlitsch studies creatures most ... at night and thrive in the shallow, cool, wet ... A collaborative study, with MU graduate student Bill Peterman, ... biomass (total mass of an organism in an area) ...